Literature DB >> 26763968

Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA.

Feiyu Hong1, Evgenia Aga2, Anthony R Cillo3, Aarika L Yates3, Guillaume Besson3, Elizabeth Fyne3, Dianna L Koontz3, Cheryl Jennings4, Lu Zheng2, John W Mellors3.   

Abstract

Although a number of PCR-based quantitative assays for measuring HIV-1 persistence during suppressive antiretroviral therapy (ART) have been reported, a simple, sensitive, reproducible method is needed for application to large clinical trials. We developed novel quantitative PCR assays for cell-associated (CA) HIV-1 DNA and RNA, targeting a highly conserved region in HIV-1pol, with sensitivities of 3 to 5 copies/1 million cells. We evaluated the performance characteristics of the assays using peripheral blood mononuclear cells (PBMCs) from 5 viremic patients and 20 patients receiving effective ART. Total and resting CD4(+)T cells were isolated from a subset of patients and tested for comparison with PBMCs. The estimated standard deviations including interassay variability and intra-assay variability of the assays were modest, i.e., 0.15 and 0.10 log10copies/10(6)PBMCs, respectively, for CA HIV-1 DNA and 0.40 and 0.19 log10copies/10(6)PBMCs for CA HIV-1 RNA. Testing of longitudinally obtained PBMC samples showed little variation for either viremic patients (median fold differences of 0.80 and 0.88 for CA HIV-1 DNA and RNA, respectively) or virologically suppressed patients (median fold differences of 1.14 and 0.97, respectively). CA HIV-1 DNA and RNA levels were strongly correlated (r= 0.77 to 1;P= 0.0001 to 0.037) for assays performed using PBMCs from different sources (phlebotomy versus leukapheresis) or using total or resting CD4(+)T cells purified by either bead selection or flow cytometric sorting. Their sensitivity, reproducibility, and broad applicability to small numbers of mononuclear cells make these assays useful for observational and interventional studies that examine longitudinal changes in the numbers of HIV-1-infected cells and their levels of transcription.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26763968      PMCID: PMC4809955          DOI: 10.1128/JCM.02904-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Minor Contribution of Chimeric Host-HIV Readthrough Transcripts to the Level of HIV Cell-Associated gag RNA.

Authors:  Alexander O Pasternak; Laura K DeMaster; Neeltje A Kootstra; Peter Reiss; Una O'Doherty; Ben Berkhout
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

3.  Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.

Authors:  Kersten K Koelsch; Christoph Boesecke; Kristin McBride; Linda Gelgor; Paul Fahey; Ven Natarajan; David Baker; Mark Bloch; John M Murray; John Zaunders; Sean Emery; David A Cooper; Anthony D Kelleher
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

4.  Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy.

Authors:  Anthony R Cillo; David Vagratian; Margaret A Bedison; Elizabeth M Anderson; Mary F Kearney; Elizabeth Fyne; Dianna Koontz; John M Coffin; Michael Piatak; John W Mellors
Journal:  J Clin Microbiol       Date:  2014-09-03       Impact factor: 5.948

Review 5.  Emerging strategies to deplete the HIV reservoir.

Authors:  Nancie M Archin; David M Margolis
Journal:  Curr Opin Infect Dis       Date:  2014-02       Impact factor: 4.915

6.  HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.

Authors:  Guillaume J Besson; Christina M Lalama; Ronald J Bosch; Rajesh T Gandhi; Margaret A Bedison; Evgenia Aga; Sharon A Riddler; Deborah K McMahon; Feiyu Hong; John W Mellors
Journal:  Clin Infect Dis       Date:  2014-07-29       Impact factor: 9.079

Review 7.  Finding a cure for human immunodeficiency virus-1 infection.

Authors:  Joel N Blankson; Janet D Siliciano; Robert F Siliciano
Journal:  Infect Dis Clin North Am       Date:  2014-09-30       Impact factor: 5.982

8.  Selection of reliable reference genes for quantitative real-time PCR in human T cells and neutrophils.

Authors:  Carola Ledderose; Jens Heyn; Elisabeth Limbeck; Simone Kreth
Journal:  BMC Res Notes       Date:  2011-10-20

9.  Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Authors:  Alexander O Pasternak; Suzanne Jurriaans; Margreet Bakker; Jan M Prins; Ben Berkhout; Vladimir V Lukashov
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

Authors:  C Korin Bullen; Gregory M Laird; Christine M Durand; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

View more
  63 in total

1.  Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.

Authors:  Serena Spudich; Kevin R Robertson; Ronald J Bosch; Rajesh T Gandhi; Joshua C Cyktor; Hanna Mar; Bernard J Macatangay; Christina M Lalama; Charles Rinaldo; Ann C Collier; Catherine Godfrey; Joseph J Eron; Deborah McMahon; Jana L Jacobs; Dianna Koontz; Evelyn Hogg; Alyssa Vecchio; John W Mellors
Journal:  J Clin Invest       Date:  2019-07-15       Impact factor: 14.808

2.  HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy.

Authors:  William R McManus; Michael J Bale; Jonathan Spindler; Ann Wiegand; Andrew Musick; Sean C Patro; Michele D Sobolewski; Victoria K Musick; Elizabeth M Anderson; Joshua C Cyktor; Elias K Halvas; Wei Shao; Daria Wells; Xiaolin Wu; Brandon F Keele; Jeffrey M Milush; Rebecca Hoh; John W Mellors; Stephen H Hughes; Steven G Deeks; John M Coffin; Mary F Kearney
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

3.  Intact HIV Proviruses Persist in Children Seven to Nine Years after Initiation of Antiretroviral Therapy in the First Year of Life.

Authors:  Mary Grace Katusiime; Elias K Halvas; Imogen Wright; Kevin Joseph; Michael J Bale; Bronwyn Kirby-McCullough; Susan Engelbrecht; Wei Shao; Wei-Shau Hu; Mark F Cotton; John W Mellors; Mary F Kearney; Gert U van Zyl
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

Review 4.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

5.  A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation.

Authors:  Bernard J C Macatangay; Edwin K Jackson; Kaleab Z Abebe; Diane Comer; Joshua Cyktor; Cynthia Klamar-Blain; Luann Borowski; Delbert G Gillespie; John W Mellors; Charles R Rinaldo; Sharon A Riddler
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

6.  Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses.

Authors:  Sheila M Keating; Richard Brad Jones; Christina M Lalama; Ronald J Bosch; Deborah McMahon; Dylan Hampton; Joshua Cyktor; Joseph J Eron; John W Mellors; Michael P Busch; Rajesh T Gandhi
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

7.  Naive CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-competent Human Immunodeficiency Virus Type 1.

Authors:  Jennifer M Zerbato; Deborah K McMahon; Michelle D Sobolewski; John W Mellors; Nicolas Sluis-Cremer
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

8.  Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

Authors:  Cynthia L Gay; Ronald J Bosch; Justin Ritz; Jason M Hataye; Evgenia Aga; Randall L Tressler; Stephen W Mason; Carey K Hwang; Dennis M Grasela; Neelanjana Ray; Josh C Cyktor; John M Coffin; Edward P Acosta; Richard A Koup; John W Mellors; Joseph J Eron
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

9.  Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control.

Authors:  Christopher W Pohlmeyer; Veronica D Gonzalez; Alivelu Irrinki; Ricardo N Ramirez; Li Li; Andrew Mulato; Jeffrey P Murry; Aaron Arvey; Rebecca Hoh; Steven G Deeks; George Kukolj; Tomas Cihlar; Stefan Pflanz; Garry P Nolan; Gundula Min-Oo
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

10.  No evidence of HIV replication in children on antiretroviral therapy.

Authors:  Gert U Van Zyl; Mary Grace Katusiime; Ann Wiegand; William R McManus; Michael J Bale; Elias K Halvas; Brian Luke; Valerie F Boltz; Jonathan Spindler; Barbara Laughton; Susan Engelbrecht; John M Coffin; Mark F Cotton; Wei Shao; John W Mellors; Mary F Kearney
Journal:  J Clin Invest       Date:  2017-09-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.